Navigation Links
AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

Evaluable 6.4 months 25 months Patients 95% CI (5.3, 7.1) 95% CI (15.5, NR) (n=73) ------------------------------------------------------------------------- NR = Not Reached * Median PFS and median TTP were identical, as no patient deaths occurred prior to progression. ** Kaplan Meier methodology was used to determine overall survival figures.

Of particular interest was the comparison of evaluable patients who were previously refractory and the patients who were relapsed to a bortezomib-based regimen.

    Median PFS and OS for bortezomib relapsed vs. refractory were as follows:

    -------------------------------------------------------------------------
    Bortezomib Relapsed
    vs. Refractory              Median PFS*         Median OS**
    -------------------------------------------------------------------------
    Bortezomib Relapsed         8.8 months            Not Reached at
    (n=20)           95% CI (6.3, 11.2)    38+ months  95% CI
                                                      (25, NR)
    -------------------------------------------------------------------------
    Bortezomib Refractory       5.7 months            22.5 months
    (n=53)           95% CI (4.3, 6.4)     95% CI (12.3, NR)
    -------------------------------------------------------------------------

    * Median PFS and median TTP were identical, as no patient deaths
    occurred prior to progression.
    ** Kaplan Meier methodology was used to determine overall survival
    figures.

No unexpected adverse events have been observed. Toxicities were manageable with supportive care.

"We congratulate our partner Keryx and their principle investigators Dr. Richardson and Dr. Anderson for the encouraging results for perifosine in multiple myeloma which further demonstrate perifosine's potential as a novel treatment for this indication. We now look for
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 ... of Kyoto University and Takeda Pharmaceutical Company Limited ... to develop clinical applications of induced pluripotent stem ... mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA ... designed to expedite multiple research projects for drug ...
(Date:4/16/2015)... Francisco, CA (PRWEB) April 16, 2015 ... scheduled to report first quarter results on Thursday, April ... announcement, Cytokinetics’ senior management will host a conference call ... financial results and the company’s outlook for the future. ... can be accessed from the homepage and in the ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Proove ... Buzz of BIO Contest for the 2015 ... (BIO), the 2015 BIO International Convention will take place ... Pennsylvania. During the Buzz of BIO contest, industry leaders ... see present at the conference. The community voting period ...
(Date:4/16/2015)... 2015 Regis Technologies looks forward to ... Cancer Research (AACR) annual meeting. Regis will exhibit at ... Saturday, April 18, in Philadelphia and running through April ... of the oldest and largest organization focused on cancer ... and partners with survivors to promote awareness and research ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2
... Shrink Nanotechnologies, Inc. ("Shrink") ... innovative nanotechnology company developing products and licensing opportunities ... sensors and biotechnology research and development tools businesses, ... – the StemDisc450™, a high-yield, low cost, patent-pending ...
... ... ... var shortURL = ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
... Connected , the one-of-a-kind program of transformation and ... to Fresno, California on Friday and Saturday, November 5 ... Connected honors California,s Central Valley ... (Photo:   http://photos.prnewswire.com/prnh/20101015/LA82180 ) (Photo: ...
Cached Biology Technology:Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype 2Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype 3Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype 4Excerpta Medica Joins Adelphi Worldwide 2Excerpta Medica Joins Adelphi Worldwide 3Excerpta Medica Joins Adelphi Worldwide 4Excerpta Medica Joins Adelphi Worldwide 5Excerpta Medica Joins Adelphi Worldwide 6Excerpta Medica Joins Adelphi Worldwide 7Excerpta Medica Joins Adelphi Worldwide 8Connected! at The Fresno Revue 2Connected! at The Fresno Revue 3
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... CryoSat was launched in 2010 to measure sea-ice thickness in ... been exploited for other studies. High-resolution mapping of the topography ... ice mission,s repertoire. The main objective of the polar-orbiting ... and monitor changes in the ice sheets that blanket Greenland ...
... borders with colourful bedding plants, scientists at the Universities of ... attractive to bees rather than humans. Published today in the ... reveals that Velcro-like cells on plant petals play a crucial ... wind gets up., The study focuses on special cells found ...
... led by researchers from McGill University provides new insights into ... finding that promises to contribute to the study of heart ... The research, published in the Proceedings of the National ... in the heart wall are locally arranged in a special ...
Cached Biology News:CryoSat goes to sea 2Blowing in the wind: How hidden flower features are crucial for bees 2Study provides new insights into structure of heart muscle fibers 2